Search for: "Bristol-Myers Squibb U.S. Pharmaceutical Group" Results 1 - 20 of 42
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jun 2021, 4:15 am by Logan Murr
A group of intellectual property professors; GlaxoSmithKline plc; and Biogen Inc., Bristol-Myers Squibb Company, Corning Incorporated, and Merck Sharp & Dohme Corp. filed amicus briefs. [read post]
5 May 2009, 5:57 am
And a group of Bristol-Myers lawsuits over the blood-thinner Plavix may now proceed to trial in federal court in Trenton, New Jersey. [read post]
4 Aug 2016, 9:24 am by Neumann Law Group
It is Bristol-Myers Squibb’s top-selling drug; it earned the pharmaceutical company $6.4 billion in 2013. [read post]
19 Jun 2015, 6:30 am by Michael B. Stack
Food and Drug Administration (FDA) approved the first AB-rated generics to Bristol-Myers Squibb and Otsuka’s Abilify® (aripiprazole) tablets, an atypical antipsychotic drug commonly used for treating schizophrenia and bipolar disorder. [read post]
17 Jul 2017, 2:03 pm by Nancy E. Halpern, D.V.M.
To address these issues and concerns head on, the New Jersey Association of Biomedical Research recently hosted one of the most significant efforts to promote biomedical research advocacy, the “Biomedical Research Summit,” presented by Bristol-Myers Squibb, also sponsored by Covance, Charles River Laboratories, s-tune software, Inc., Marshall BioResources, and Allentown, Inc. [read post]
4 Dec 2007, 6:33 pm
Bristol-Myers Squibb was the first company to develop and patent a liquid pharmaceutical composition of megestrol acetate and had a patent that taught that stable suspensions of megestrol acetate can be created but that the type and concentration of the surfactant in solution is critical to creating a stable flocculated suspension. [read post]
19 Mar 2010, 7:45 am by Carey, Danis & Lowe
If Bristol-Myers Squibb and Sanofi-Aventis knew of these problems and did not warn doctors and patients appropriately, they could be held responsible for harm suffered by patients who took their drug. [read post]
9 Jul 2015, 3:28 pm by Dr. Shezad Malik
Xarelto, has grabbed a 32 percent market share in the highly competitive anticoagulant market, significantly ahead of Boehringer’s Pradaxa and Bristol-Myers Squibb’s Eliquis, the other two new anticoagulants in the market. [read post]